Gastric acid inhibitory and gastric protective effects of Cannabis and cannabinoids

Asian Pacific Journal of Tropical Medicine

Volumn 9, Issue 5, 2016, Pages 413-419

  Abdel Salam, Omar ^a  

^a NATIONAL RESEARCH CENTRE   (Egypt)

Author keywords

Cannabis sativa; Gastric acid; Gastric mucosa

Indexed keywords

ANANDAMIDE; ARACHIDONYL 2 CHLOROETHYLAMIDE; CANNABINOID; CANNABIS; DRONABINOL; PROTECTIVE AGENT; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; DRUG MECHANISM; GASTRIC MUCOSA; HUMAN; NONHUMAN; PRIORITY JOURNAL; STOMACH ACID SECRETION; STOMACH INJURY; STOMACH PROTECTION; STOMACH ULCER; VASODILATATION;

EID: 84975745644     PISSN: 19957645     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.apjtm.2016.04.021     Document Type: Article

References (84)

1. [1] Ashton, C.H., Pharmacology and effects of cannabis: a brief review. Br J Psychiatr 178 (2001), 101–106.
2. [2] Elsohly, M.A., Slade, D., Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci 78:5 (2005), 539–548.
3. [3] Brenneisen, R., Chemistry and analysis of phytocannabinoids and other cannabis constituents. ElSohly, M.A., (eds.) Forensic science and medicine: marijuana and the cannabinoids, 2006, Humana, Totowa, 17–49.
4. [4] Mechoulam, R., Gaoni, Y., Recent advances in the chemistry of hashish. Fortschr Chem Org Naturst 25 (1967), 175–213.
5. [5] Pertwee, R.G., Ross, R.A., Cannabinoid receptors and their ligands. Prostaglandins Leukot Essent Fatty Acids 66:2–3 (2002), 101–121.
6. 2 receptors. Pharmacol Ther 74:2 (1997), 129–180.
7. [7] Pertwee, R.G., Pharmacological actions of cannabinoids. Handb Exp Pharmacol 168 (2005), 1–51.
8. [8] Fride, E., Endocannabinoids in the central nervous system-an overview. Prostaglandins Leukot Essent Fatty Acids 66:2–3 (2002), 221–233.
9. [9] Freund, T.F., Katona, I., Piomelli, D., Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 83:3 (2003), 1017–1066.
10. [10] Di Marzo, V., Bifulco, M., De Petrocellis, L., The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 3:9 (2004), 771–784.
11. [11] Di Marzo, V., Petrosino, S., Endocannabinoids and the regulation of their levels in health and disease. Curr Opin Lipidol 18:2 (2007), 129–140.
12. [12] Mackie, K., Stella, N., Cannabinoid receptors and endocannabinoids: evidence for new players. AAPS J 8:2 (2006), E298–E306.
13. [13] Iversen, L., The science of marijuana. 2007, Oxford University Press, Oxford.
14. ®) in the management of spasticity associated with multiple sclerosis. Expert Rev Neurother 11:5 (2011), 627–637.
15. [15] Seamon, M.J., Fass, J.A., Maniscalco-Feichtl, M., Abu-Shraie, N.A., Medical marijuana and the developing role of the pharmacist. Am J Health Syst Pharm 64:10 (2007), 1037–1044.
16. [16] Ware, M.A., Fitzcharles, M.A., Joseph, L., Shir, Y., The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesth Analg 110:2 (2010), 604–610.
17. [17] Ware, M.A., Wang, T., Shapiro, S., Robinson, A., Ducruet, T., Huynh, T., et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ 182:14 (2010), E694–E701.
18. [18] Aggarwal, S.K., Carter, G.T., Sullivan, M.D., ZumBrunnen, C., Morrill, R., Mayer, J.D., Medicinal use of cannabis in the United States: historical perspectives, current trends, and future directions. J Opioid Manag 5:3 (2009), 153–168.
19. [19] Müller-Vahl, K.R., Kolbe, H., Schneider, U., Emrich, H.M., Cannabis in movement disorders. Forsch Komplementarmed 6:Suppl 3 (1999), 23–27.
20. [20] Scotter, E.L., Abood, M.E., Glass, M., The endocannabinoid system as a target for the treatment of neurodegenerative disease. Br J Pharmacol 160:3 (2010), 480–498.
21. [21] Massa, F., Monory, K., Endocannabinoids and the gastrointestinal tract. J Endocrinol Invest 29:Suppl 3 (2006), 47–57.
22. [22] Izzo, A.A., Sharkey, K.A., Cannabinoids and the gut: new developments and emerging concepts. Pharmacol Ther 126:1 (2010), 21–38.
23. [23] Nalin, D.R., Levine, M.M., Rhead, J., Bergquist, E., Rennels, M., Hughes, T., et al. Cannabis, hypochlorhydria, and cholera. Lancet 2:8095 (1978), 859–862.
24. [24] Castillo, G., Pachajoa, H., Villota, S., Zurita, A.E., Palacios, M., Gutiérrez, O., Study of the gastric acid anti-secretory activity of Cannabis sativa in an animal model. Colomb Médica 37:4 (2006), 254–257.
25. [25] Abdel-Salam, O.M.E., Salama, R.A.A., El-Denshary, E.-E., Sleem, A.A., El-Shamarka, M.E.S., Hassan, N.S., Effect of Cannabis sativa extract on gastric acid secretion, oxidative stress and gastric mucosal integrity in rats. Comp Clin Pathol 24 (2015), 1417–1434.
26. [26] Coruzzi, G., Adami, M., Coppelli, G., Frati, P., Soldani, G., Inhibitory effect of the cannabinoid receptor agonist WIN55, 212-2 on pentagastrin-induced gastric acid secretion in the anaesthetized rat. Naunyn Schmiedebergs Arch Pharmacol 360:6 (1999), 715–718.
27. [27] Adami, M., Frati, P., Bertini, S., Kulkarni-Narla, A., Brown, D.R., de Caro, G., et al. Gastric antisecretory role and immunohistochemical localization of cannabinoid receptors in the rat stomach. Br J Pharmacol 135:7 (2002), 1598–1606.
28. 9-tetrahydrocannabinol in rat isolated stomach. Eur J Pharmacol 65:2 (1980), 317–318.
29. 1 receptor and gastric acid secretion. Dig Dis Sci 52:11 (2007), 3102–3103.
30. [30] Beaumont, H., Jensen, J., Carlsson, A., Ruth, M., Lehmann, A., Boeckxstaens, G., Effect of delta9-tetrahydrocannabinol, a cannabinoid receptor agonist, on the triggering of transient lower oesophageal sphincter relaxations in dogs and humans. Br J Pharmacol 156:1 (2009), 153–162.
31. [31] Haney, M., Ward, A.S., Comer, S.D., Foltin, R.W., Fischman, M.W., Abstinence symptoms following smoked marijuana in humans. Psychopharmacology 141:4 (1999), 395–404.
32. [32] Schubert, M.L., Peura, D.A., Control of gastric acid secretion in health and disease. Gastroenterology 134:7 (2008), 1842–1860.
33. [33] Aihara, T., Nakamura, E., Amagase, K., Tomita, K., Fujishita, T., Furutani, K., et al. Pharmacological control of gastric acid secretion for the treatment of acid-related peptic disease: past, present, and future. Pharmacol Ther 98:1 (2003), 109–127.
34. [34] Storr, M., Gaffal, E., Saur, D., Schusdziarra, V., Allescher, H.D., Effect of cannabinoids on neural transmission in rat gastric fundus. Can J Physiol Pharmacol 80:1 (2002), 67–76.
35. [35] Coruzzi, G., Adami, M., Guaita, E., Menozzi, A., Bertini, S., Giovannini, E., et al. Effects of cannabinoid receptor agonists on rat gastric acid secretion: discrepancy between in vitro and in vivo data. Dig Dis Sci 51:2 (2006), 310–317.
36. 1 receptors are expressed by parietal cells of the human gastric mucosa. J Histochem Cytochem 56:5 (2008), 511–516.
37. 2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 153:2 (2008), 199–215.
38. 1 receptors in specific regions of dorsal vagal complex to inhibit emesis in ferrets. Am J Physiol Gastrointest Liver Physiol 285:3 (2003), G566–G576.
39. [39] Adami, M., Zamfirova, R., Sotirov, E., Tashev, R., Dobrinova, Y., Todorov, S., et al. Gastric antisecretory effects of synthetic cannabinoids after central or peripheral administration in the rat. Brain Res Bull 64:4 (2004), 357–361.
40. 9-tetrahydrocannabinol in the Shay rat test. Pharmacology 17:3 (1978), 173–177.
41. [41] De Souza, H., Trajano, E., de Carvalho, F.V., Palermo Neto, J., Effects of acute and long-term cannabis treatment of restraint-induced gastric ulceration in rats. Jpn J Pharmacol 28:3 (1978), 507–510.
42. [42] Kinsey, S.G., Nomura, D.K., O’ Neal, S.T., Long, J.Z., Mahadevan, A., Cravatt, B.F., et al. Inhibition of monoacylglycerol lipase attenuates nonsteroidal anti-inflammatory drug-induced gastric hemorrhages in mice. J Pharmacol Exp Ther 338:3 (2011), 795–802.
43. (9)-tetrahydrocannabinol blocks gastric hemorrhages induced by the nonsteroidal anti-inflammatory drug diclofenac sodium in mice. Eur J Pharmacol 715:1–3 (2013), 111–116.
44. [44] Wallace, J.L., Flannigan, K.L., McKnight, W., Wang, L., Ferraz, J.G., Tuitt, D., Pro-resolution, protective and anti-nociceptive effects of a cannabis extract in the rat gastrointestinal tract. J Physiol Pharmacol 64:2 (2013), 167–175.
45. [45] Borgelt, L.M., Franson, K.L., Nussbaum, A.N., Wang, G.S., The pharmacologic and clinical effects of medical cannabis. Pharmacotherapy 33:2 (2013), 195–209.
46. 1-mediated inhibition of stress-induced gastric ulcers in rats. Naunyn Schmiedebergs Arch Pharmacol 363:2 (2001), 241–244.
47. [47] Dembiński, A., Warzecha, Z., Ceranowicz, P., Dembiński, M., Cieszkowski, J., Pawlik, W.W., et al. Cannabinoids in acute gastric damage and pancreatitis. J Physiol Pharmacol 57:Suppl 5 (2008), 137–154.
48. 1 receptor agonist, protects against aspirin-induced gastric ulceration. Pharmazie 61:4 (2006), 341–342.
49. [49] Shujaa, N., Zadori, Z.S., Ronai, A.Z., Barna, I., Mergl, Z., Mozes, M.M., et al. Analysis of the effect of neuropeptides and cannabinoids in gastric mucosal defense initiated centrally in the rat. J Physiol Pharmacol 60:Suppl 7 (2009), 93–100.
50. 1 receptor in rat brain. Proc Biol Sci 265:1410 (1998), 2081–2085.
51. [51] Sasso, O., Bertorelli, R., Bandiera, T., Scarpelli, R., Colombano, G., Armirotti, A., et al. Peripheral FAAH inhibition causes profound antinociception and protects against indomethacin-induced gastric lesions. Pharmacol Res 65:5 (2012), 553–563.
52. [52] Di Marzo, V., De Petrocellis, L., Bisogno, T., The biosynthesis, fate and pharmacological properties of endocannabinoids. Pertwee, R.G., (eds.) Cannabinoids. Handbook of experimental pharmacology, 168, 2005, Springer-Verlag, Heidelberg, Germany, 147–185.
53. [53] Kinsey, S.G., Wise, L.E., Ramesh, D., Abdullah, R., Selley, D.E., Cravatt, B.F., et al. Repeated low-dose administration of the monoacylglycerol lipase inhibitor JZL184 retains cannabinoid receptor type 1-mediated antinociceptive and gastroprotective effects. J Pharmacol Exp Ther 345:3 (2013), 492–501.
54. [54] Aase, S., Disturbances in the balance between aggressive and protective factors in the gastric and duodenal mucosa. Scand J Gastroenterol 163:Suppl (1989), 17–23.
55. [55] Shorrock, C.J., Rees, W.D., Overview of gastroduodenal mucosal protection. Am J Med 84:2A (1988), 25–34.
56. [56] Wallace, J.L., Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself?. Physiol Rev 88:4 (2008), 1547–1565.
57. [57] Tarnawski, A.S., Ahluwalia, A., Jones, M.K., The mechanisms of gastric mucosal injury: focus on microvascular endothelium as a key target. Curr Med Chem 19:1 (2012), 4–15.
58. [58] Yandrapu, H., Sarosiek, J., Protective factors of the gastric and duodenal mucosa: an overview. Curr Gastroenterol Rep, 17(6), 2015, 24.
59. [59] Mózsik, Gy, Nagy, L., Pár, A., Rainsford, K.D., Cell injury and protection in gastrointestinal tract: from basic science to clinical perspectives. 1997, Kluwer Academic Publisher, Dordrecht, Boston, London.
60. [60] Robert, A., Nezamis, J.E., Lancaster, C., Hanchar, A.J., Cytoprotection by prostaglandins in rats. Prevention of gastric necrosis produced by alcohol, HCl, NaOH, hypertonic NaCl, and thermal injury. Gastroenterology 77:3 (1979), 433–443.
61. [61] Mózsik, G., Dömötör, A., Rumi, G., Szekeres, G., Gastrointestinal cytoprotection: from basic science to clinical perspectives. Inflammopharmacology 15:2 (2007), 49–60.
62. [62] MacNaughton, W.K., Williamson, T.E., Morris, G.P., Adaptive cytoprotection by 0.25 M HCl is truly ‘cytoprotective’ and may not depend upon elevated levels of prostaglandin synthesis. Can J Physiol Pharmacol 66:8 (1988), 1075–1081.
63. [63] Jacobson, E.D., Direct and adaptive cytoprotection. Dig Dis Sci 31:2 Suppl (1986), 28S–31S.
64. [64] Boku, K., Ohno, T., Saeki, T., Hayashi, H., Hayashi, I., Katori, M., et al. Adaptive cytoprotection mediated by prostaglandin I(2) is attributable to sensitization of CRGP-containing sensory nerves. Gastroenterology 120:1 (2001), 134–143.
65. [65] Hollister, L.E., Cannabis – 1988. Acta Psychiatr Scand 345:Suppl (1988), 108–118.
66. [66] ElShohly, M.A., Chemical constituents of cannabis. Grotenhermen, F., Russo, E., (eds.) Cannabis and cannabinoids. pharmacology, toxicology and therapeutic potential, 2002, Haworth Press Inc, New York, 27–36.
67. [67] Tambe, Y., Tsujiuchi, H., Honda, G., Ikeshiro, Y., Tanaka, S., Gastric cytoprotection of the non-steroidal anti-inflammatory sesquiterpene, beta-caryophyllene. Planta Med 62:5 (1996), 469–470.
68. [68] Allen, A., Flemstrom, G., Garner, A., Kivilaakso, E., Gastroduodenal mucosal protection. Physiol Rev 73:4 (1993), 823–857.
69. [69] Allen, A., Flemstrom, G., Gastroduodenal mucus bicarbonate barrier: protection against acid and pepsin. Am J Physiol Cell Physiol 288:1 (2005), C1–C19.
70. [70] Allen, A., Pearson, J.P., Blackburn, A., Coan, R.M., Hutton, D.A., Mall, A.S., Pepsins and the mucus barrier in peptic ulcer disease. Scand J Gastroenterol 146:Suppl (1988), 50–57.
71. [71] Naito, Y., Suematsu, M., Yoshikawa, T., Free Radical biology in digestive diseases. Frontiers of gastrointestinal research. 2011, Karger, Basel, Switzerland.
72. [72] Whittle, B.J.R., Neuronal and endothelium-derived mediators in the modulation of the gastric microcirculation: integrity in the balance. Br J Pharmacol 110:1 (1993), 3–17.
73. [73] Wallace, J.L., Miller, M.J., Nitric oxide in mucosal defense: a little goes a long way. Gastroenterology 119:2 (2000), 512–520.
74. [74] Calatayud, S., Barrachina, D., Esplugues, J.V., Nitric oxide: relation to integrity, injury, and healing of the gastric mucosa. Microsc Res Tech 53:5 (2001), 325–335.
75. [75] Wallace, J.L., Ma, L., Inflammatory mediators in gastrointestinal defense and injury. Exp Biol Med (Maywood) 226:11 (2001), 1003–1015.
76. [76] Rainsford, K.D., Microvascular injury during gastric mucosal damage by anti-inflammatory drugs in pigs and rats. Agents Actions 13:5–6 (1983), 457–460.
77. [77] Tarnawski, A., Stachura, J., Gergely, H., Hollander, D., Gastric microvascular endothelium: a major target for aspirin-induced injury and arachidonic acid protection. An ultrastructural analysis in the rat. Eur J Clin Invest 20:4 (1990), 432–440.
78. [78] Szabo, S., Mechanisms of mucosal injury in the stomach and duodenum: time-sequence analysis of morphologic, functional, biochemical and histochemical studies. Scand J Gastroenterol 127:Suppl (1987), 21–28.
79. [79] Howard, T.J., Passaro, E. Jr., Guth, P.H., Isoproterenol prevents ethanol-induced microvascular stasis and deep histologic injury in rat gastric mucosa. Dig Dis Sci 38:7 (1993), 1201–1209.
80. [80] Guth, P.H., Paulsen, G., Nagata, H., Histologic and microcirculatory changes in alcohol-induced gastric lesions in the rat: effect of prostaglandin cytoprotection. Gastroenterology 87:5 (1984), 1083–1090.
81. [81] Holzer, P., Peskar, B.M., Peskar, B.A., Amann, R., Release of calcitonin gene-related peptide induced by capsaicin in the vascularly perfused rat stomach. Neurosci Lett 108:1–2 (1990), 195–200.
82. [82] Holzer, P., Livingston, E.H., Saria, A., Guth, P.H., Sensory neurons mediate protective vasodilatation in rat gastric mucosa. Am J Physiol 260:3 Pt 1 (1991), G363–G370.
83. [83] Abdel Salam, O.M., Szolcsányi, J., Pórszász, R., Mózsik, G., Effect of capsaicin and resiniferatoxin on gastrointestinal blood flow in rats. Eur J Pharmacol 305:1–3 (1996), 127–136.
84. [84] Breyne, J., Van de Voorde, J., Vanheel, B., Characterization of the vasorelaxation to methanandamide in rat gastric arteries. Can J Physiol Pharmacol 84:11 (2006), 1121–1132.